SCHEMBL2882989

SCHEMBL2882989

O=C(O)c1ccc(Cn2nc(-c3cc(F)c(F)c(F)c3)cc2C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 10/20 0.52
GIPR P48546 3/20 0.50
PTGER4 P35408 3/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2C8 P10632 1/20 0.49
CYP2C9 P11712 1/20 0.49
KCNH2 Q12809 1/20 0.49
HDAC1 Q13547 1/20 0.48
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
FLT1 P17948 1/20 0.46
KDR P35968 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881085 0.92 GCGR (0.49) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2883051 0.89 GCGR (0.67) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2883978 0.88 GCGR (0.52) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2666819 0.86 GCGR (0.46) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2883860 0.86 GCGR (0.51) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL4392209 0.82 FLT1 (0.44) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2884259 0.76 MEN1 (0.55) HDAC1ALDH1A1GAASMN1; SMN2MAPT
SCHEMBL9071146 0.76 NPSR1 (0.41) GCGRGIPRCYP3A4CYP2C8CYP2C9
SCHEMBL2885559 0.73 PTGDR2 (0.49) GCGRGIPRPTGER4HDAC1ALDH1A1
SCHEMBL2883065 0.73 PTGDR2 (0.49) GCGRGIPRPTGER4HDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7649009-B2 N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis MERCK & CO., INC. (US) 2010-01-19 US disclosed
EP-1765335-B1 PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-11-25 EP disclosed
US-20070203186-A1 Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use MERCK & CO., INC. (US) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203186-A1 Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use AADAC, GOT2, GLS2 GCGR 58/4885GIPR 70/4885PTGER4 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.